sponsored
PatientsVille.com Logo

PatientsVille

Bufferin Medical Research Studies

Up-to-date List of Bufferin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Bufferin Medical Research Studies

Rank Status Study
1 Recruiting Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
Conditions: Asthma, Aspirin-Induced;   Aspirin Exacerbated Asthma
Intervention: Drug: Prasugrel
Outcome Measures: Change in Total Nasal Symptom Score(TNSS)from baseline to aspirin challenge/desensitization.;   Change from baseline expression levels of COX-2 transcript and protein in peripheral blood leukocytes of subjects with AERD after 8 weeks of treatment with aspirin.;   Difference in participant's provocative dose of aspirin when pretreated with prasugrel versus placebo;   Change in urinary LTE4;   Effect desensitization to and treatment with aspirin has on baseline characteristics of AERD
2 Unknown  Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery
Condition: Postoperative; Dysfunction Following Cardiac Surgery
Intervention: Drug: Aspirin
Outcome Measures: Serum Thromboxane: Define an inadequate aspirin response as a value >0.69 ng/ml, which is 2 SD above the mean of aspirin-treated patients;   Arachidonic Acid Induced Light Transmission Aggregometry (LTA): Aggregation will be expressed as the maximum percent change in light transmittance from baseline, with platelet-poor plasma used as a reference.;   Arachidonic Acid Induced Multiple Electrode Platelet Aggregometry (MEA):Aggregation was recorded for 6 minutes and will be reported as the area under the curve (aggregation units x min).;   DNA genetic analyses for single nucleotide polymorphisms
3 Recruiting Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial
Conditions: Aortic Valve Disease;   Myocardial Infarction;   Stroke
Interventions: Drug: Aspirin (80 mg/d) + clopidogrel (75 mg/d);   Drug: Aspirin
Outcome Measures: Incidence of death, MI, ischemic stroke/Transient ischemic attack (TIA) or life threatening/major bleeding;   Incidence of death, MI, ischemic stroke/TIA or life threatening/major bleeding;   Incidence of MI or ischemic stroke;   Incidence of major bleeding;   Cardiovascular death;   Cost-effectiveness of clopidogrel on top of aspirin following TAVI;   Rate of minor bleeding
4 Unknown  Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.
Condition: Ischemic Stroke
Interventions: Drug: Aspirin;   Biological: blood sample
Outcome Measures: Measure of platelet activity recovery within 24 hours after the first 300 mg oral dose of aspirin given at hospital at the acute phase of ischemic stroke;   Measure of effect of the first 300 mg oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated
5 Unknown  Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery
Condition: Coronary Arteriosclerosis
Intervention: Drug: Aspirin
Outcome Measures: change in the levels of TXB2 in serum at 12 and 24 hours after administration of aspirin;   change in the levels of 12-HETE in serum at 12 and 24 hours after administration of aspirin;   change in the levels of 11-dehydro TXB2 urinary at 12 and 24 hours after administration of aspirin;   change in the levels of 8-iso-PGF2 alpha urinary at 12 and 24 hours after administration of aspirin;   change in the levels of 2-3 dinor-6-chetoPGF1 alpha at 12 and 24 hours after administration of aspirin;   change in the levels of Verify-NOW Aspirin, platelets crosslinked at 12 and 24 hours after administration of aspirin
6 Not yet recruiting The Effect Of Aspirin On Survival in Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Survival;   Aspirin
Interventions: Drug: Aspirin 75 mg;   Other: no aspirin
Outcome Measures: Survival - alive or dead (A standard cancer trial outcome). This will be assessed via the UK national strategic tracking service;   Side effects eg gastrointestinal
7 Recruiting Chronotherapy With Low-dose Aspirin for Primary Prevention
Condition: Type 2 Diabetes
Intervention: Drug: aspirin
Outcome Measures: To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration in subjects with impaired fasting glucose or type 2 diabetes on primary prevention of cardiovascular, cerebrovascular and renal fatal, and non-fatal events.;   To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of cardiovascular fatal and non-fatal events (including cardiovascular death, myocardial infarction, angina pectoris, and coronary revascularization).;   To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of cerebrovascular fatal and non-fatal events (including hemorrhagic stroke, ischemic stroke, and transient ischemic attack).;   To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration on primary prevention of chronic kidney disease and/or congestive heart failure, and/or peripheral artery disease.;   To demonstrate that 100 mg/day ASA at bedtime offers a similar safety profile than 100 mg/day ASA upon awakening;   To demonstrate that compliance with 100 mg/day ASA at bedtime is similar to that with 100 mg/day ASA upon awakening.;   To evaluate, for all previous objectives, potential gender differences in the benefits of low-dose ASA for primary prevention.;   To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between patients with and without diabetes.;   To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between subjects with and without metabolic syndrome.
8 Recruiting Effectiveness of Night Administration of Low Dose Aspirin in Hypertensive Patients
Condition: Hypertension
Interventions: Drug: acetylsalicylic acid 100 mg in the evening and placebo in the morning;   Drug: Acetylsalicylic acid at day time;   Drug: Placebo
Outcome Measures: Mean SBP and DBP measured with Ambulatory Blood Pressure Monitoring (ABPM) over a 24 hour period;   Mean of day/night SBP and DBP ratios measured with Ambulatory Blood Pressure monitoring Monitoring;   The mean of heart rate (HR) and the mean of pulse pressure (PP);   Percentage of adverse events related to ASA evening administration versus day administration
9 Unknown  In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction
Condition: Healthy
Interventions: Procedure: Aspirin ingestion followed by doing a Bleeding Volume Test;   Procedure: Gatorade Placebo followed by Bleeding Volume Test.
Outcome Measure: Sensitivity, Specificity & ROC curve characteristics of the Bleeding Volume Test
10 Unknown  Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
Condition: Aspirin Exacerbated Respiratory Disease
Intervention:
Outcome Measures: eicosanoid metabolites concentration in plasma and urine;   safety and tolerability of the low dose aspirin challenge
11 Unknown  Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events
Conditions: Polyvascular Disease;   Cardiovascular Disease
Interventions: Drug: aspirin;   Drug: clopidogrel;   Drug: clopidogrel plus aspirin
Outcome Measures: The aim of the present study is to demonstrate the superior antinflammatory effect of Clopidogrel and Aspirin vs Aspirin or Clopidogrel alone in term of levels of selected circulating inflammatory markers;   The aim of the present study is to demonstrate the superior antiplatelet effect of Clopidogrel and Aspirin vs Aspirin or Clopidogrel alone in term of TXA2 serum levels
12 Not yet recruiting Prospective Study Comparing Aspirin Versus Placebo and Blood Loss in Inguinal Hernia Repair
Conditions: Hernia, Inguinal;   Postoperative Complications;   Postoperative Hemorrhage
Interventions: Drug: Aspirin;   Drug: Placebo
Outcome Measures: intraoperative blood loss;   Number of Participants with Serious and Non-Serious Adverse Events
13 Recruiting Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B
Condition: Postoperative Dysfunction Following Cardiac Surgery
Intervention: Drug: Aspirin
Outcome Measures: Serum Thromboxane Concentration (ng/ml);   Arachidonic Acid Induced Light Transmission Aggregometry (LTA): Aggregation will be expressed as the maximum percent change in light transmittance from baseline, with platelet-poor plasma used as a reference.;   DNA genetic analyses for single nucleotide polymorphisms
14 Unknown  Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients
Condition: End-Stage Renal Disease
Interventions: Drug: aspirin;   Drug: Placebo
Outcome Measures: the prevalence of aspirin resistance;   the incidence of vascular events (myocardial infarction, cardiac death, stroke, vascular access thrombosis, or revascularization procedure)
15 Recruiting Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.
Condition: To Investigate the Effects of Low Dose Aspirin and Low Molecular Weight Heparin in IVF Out Come
Interventions: Drug: Low molecular weight heparin;   Drug: Low dose aspirin;   Drug: Heparin & aspirin;   Other: NaCl
Outcome Measures: Biological pregnancy test;   Fetal heart/Gestational sac
16 Recruiting N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder
Condition: Bipolar Disorder
Interventions: Drug: Asprin;   Dietary Supplement: N-acetyl-cysteine (NAC);   Drug: Asprin and NAC;   Drug: Sugar Pill
Outcome Measures: Proportion of patients demonstrating > 50% decrease in depression scores on the MADRS, as a function of treatment (on aspirin treatment only).;   Modulators of therapeutic response;   Proportion of patients demonstrating > 50% decrease in depression scores on the;   Proportion of patients demonstrating > 50% decrease in depression scores on the MADRS, as a function of treatment (on NAC/Aspirin combination treatment).
17 Recruiting BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
Condition: Acute Coronary Syndrome
Intervention: Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Outcome Measures: The primary efficacy variable will be the TXB2 (Thromboxane B2) concentration at 5 minutes after study drug administration.;   TXB2 (Thromboxane B2) values at 20 minutes;   Platelet aggregation inhibition;   Serum prostacyclin levels;   Incidence of post randomization deaths from all causes, cardiovascular deaths, myocardial re/infarctions and ischemic strokes;   Safety laboratory examinations, vital signs, physical examination, ECG, adverse events collection;   Incidence of all post randomization strokes of unknown etiology;   Incidence of all post randomization bleedings assessed according to the TIMI (thrombolysis in myocardial infarction) classification including hemorrhagic stroke;   Hospital mortality during the hospitalization for ACS (Acute Coronary Syndrome)
18 Recruiting Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PL2200 Aspirin Capsules;   Drug: Enteric-coated aspirin caplets
Outcome Measures: Pharmacodynamic bioequivalence;   Pharmacokinetic bioequivalence;   Safety and tolerability
19 Not yet recruiting Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy
Conditions: Acute Coronary Syndrome;   Platelet Reactivity on Novel P2Y12 Inhibitors With and Without Aspirin
Intervention: Drug: Aspirin
Outcome Measures: Platelet reactivity;   platelet reactivity
20 Recruiting Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
Condition: Aspirin Exacerbated Respiratory Disease
Intervention: Drug: omalizumab
Outcome Measures: Spirometry (FEV1) testing to assess the efficacy of Xolair on aspirin induced bronchospasm during aspirin desensitization in patients with AERD.;   Changes in serum and urinary markers of eosinophil activation during desensitization and change in urinary LTE4 during bronchospasm. Assessment of aspirin dose that provokes reaction.

These studies may lead to new treatments and are adding insight into Bufferin etiology and treatment.

A major focus of Bufferin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Bufferin